Busulfex Articles
Kyowa Hakko Kirin returns rights to Busulfex to Otsuka
17 September 2012
Pharmalink granted US patent for Busulipo
21 April 2008
Otsuka closes buy of PDL products
17 March 2008
Genmab buys PDL facility for $240M
3 March 2008
Otsuka buys PDL's Busulfex for $200M
24 December 2007
PDL's 3rd-qtr loss falls 9% despite charges
26 November 2007
PDL share price falls 19.5% on announcement of corporate restructuring and drug divestment
10 September 2007
PDL BioPharma swings into 2nd-qtr profit
13 August 2007
PDL's 4th-qtr net loss widens to $72.1M
5 March 2007
S-P's Temodar, Baxter's Feiba etc OKed in Japan
15 May 2006
ESP acquires Busuflex in $29.5M deal
16 June 2003
CPMP backing for Pierre Fabre's Busilvex
14 April 2003
Orphan Medical completes $41.1M placement
11 December 2001
Orphan product approvals
6 December 2001
Orphan Medical increases losses in 3rd-qtr
17 October 2001
Canada approves Orphan Medical's Busulfex
27 July 1999
-Orphan Medical shipsBusulfex across USA
23 February 1999
Orphan's Busulfex approved in USA
10 February 1999
FDA panel backs Busulfex approval
21 January 1999
Orphan's Busulfex Enters Regulatory Review
8 October 1998
FDA Clears Orphan's IV Busulfan
6 August 1998
Sparta Begins Phase I Trials Of Spartaject
10 July 1997
Sparta Begins Ph I With Spartaject
26 March 1997
Orphan Medical To Expand Busulfanex Ph I/II
24 February 1997
Sparta Pharmaceuticals' Spartaject busulfan: news
18 December 1995
ORPHAN MEDICAL TO WORK ON IV BUSULFAN
28 February 1994
Showing 1-26 of 26 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
